RiverVest Venture Partners — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
HealthtechSt. Louis, US
Igor R. Efimov(Director)M. Brent Shelton(Executive Officer)Paula Skjefte(Executive Officer, Director)Nick Lanners(Executive Officer)Igor Efimov(Director)
BoardEric A. Gulve(Executive Officer, Director)
Board seatJay W. Schmelter· per SEC Form D
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)Cherry Thomas(Executive Officer)Kumar Srinivasan(Executive Officer, Director)Keith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Board seatNiall O'DonnellJohn McKearn· per SEC Form D
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesAbingworthFidelity InvestmentsIntermediate Capital Group+1 more
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)Mitchell Mutz(Director)Nicholas Walrod(Director)
BoardJohn McKearn(Director)inKarl Handelsman(Director)
Co-investorsDigitalis VenturesRoche Venture Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.